Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Cash from Operations (2023 - 2025)

Tonix Pharmaceuticals Holding has reported Cash from Operations over the past 3 years, most recently at 39650000.0 for Q4 2025.

  • Quarterly results put Cash from Operations at 39650000.0 for Q4 2025, down 171.02% from a year ago — trailing twelve months through Dec 2025 was 99844000.0 (down 63.88% YoY), and the annual figure for FY2025 was 99844000.0, down 63.88%.
  • Cash from Operations for Q4 2025 was 39650000.0 at Tonix Pharmaceuticals Holding, down from 28782000.0 in the prior quarter.
  • Over the last five years, Cash from Operations for TNXP hit a ceiling of 9919000.0 in Q2 2024 and a floor of 39650000.0 in Q4 2025.
  • Median Cash from Operations over the past 3 years was 20570500.0 (2023), compared with a mean of 21897666.67.
  • Biggest five-year swings in Cash from Operations: surged 57.55% in 2024 and later plummeted 171.02% in 2025.
  • Tonix Pharmaceuticals Holding's Cash from Operations stood at 22340000.0 in 2023, then surged by 34.51% to 14630000.0 in 2024, then crashed by 171.02% to 39650000.0 in 2025.
  • The last three reported values for Cash from Operations were 39650000.0 (Q4 2025), 28782000.0 (Q3 2025), and 14833000.0 (Q2 2025) per Business Quant data.